Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
1.
Vaccine ; 42(3): 677-688, 2024 Jan 25.
Article in English | MEDLINE | ID: mdl-38114409

ABSTRACT

INTRODUCTION: Since the SARS-CoV-2 Omicron variant became dominant, assessing COVID-19 vaccine effectiveness (VE) against severe disease using hospitalization as an outcome became more challenging due to incidental infections via admission screening and variable admission criteria, resulting in a wide range of estimates. To address this, the World Health Organization (WHO) guidance recommends the use of outcomes that are more specific to severe pneumonia such as oxygen use and mechanical ventilation. METHODS: A case-control study was conducted in 24 hospitals in Japan for the Delta-dominant period (August-November 2021; "Delta") and early Omicron (BA.1/BA.2)-dominant period (January-June 2022; "Omicron"). Detailed chart review/interviews were conducted in January-May 2023. VE was measured using various outcomes including disease requiring oxygen therapy, disease requiring invasive mechanical ventilation (IMV), death, outcome restricting to "true" severe COVID-19 (where oxygen requirement is due to COVID-19 rather than another condition(s)), and progression from oxygen use to IMV or death among COVID-19 patients. RESULTS: The analysis included 2125 individuals with respiratory failure (1608 cases [75.7%]; 99.2% of vaccinees received mRNA vaccines). During Delta, 2 doses provided high protection for up to 6 months (oxygen requirement: 95.2% [95% CI:88.7-98.0%] [restricted to "true" severe COVID-19: 95.5% {89.3-98.1%}]; IMV: 99.6% [97.3-99.9%]; fatal: 98.6% [92.3-99.7%]). During Omicron, 3 doses provided high protection for up to 6 months (oxygen requirement: 85.5% [68.8-93.3%] ["true" severe COVID-19: 88.1% {73.6-94.7%}]; IMV: 97.9% [85.9-99.7%]; fatal: 99.6% [95.2-99.97]). There was a trend towards higher VE for more severe and specific outcomes. CONCLUSION: Multiple outcomes pointed towards high protection of 2 doses during Delta and 3 doses during Omicron. These results demonstrate the importance of using severe and specific outcomes to accurately measure VE against severe COVID-19, as recommended in WHO guidance in settings of intense transmission as seen during Omicron.


Subject(s)
COVID-19 Vaccines , COVID-19 , Humans , COVID-19/prevention & control , Oxygen/therapeutic use , Japan/epidemiology , Respiration, Artificial , Case-Control Studies , Vaccine Efficacy , SARS-CoV-2
2.
Case Rep Surg ; 2016: 1396568, 2016.
Article in English | MEDLINE | ID: mdl-26885430

ABSTRACT

Helicobacter cinaedi is a rare human pathogen which has various clinical manifestations such as cellulitis, bacteremia, arthritis, meningitis, and infectious endocarditis. We report an abdominal aortic aneurysm infected with Helicobacter cinaedi, treated successfully with surgical repair and long-term antimicrobial therapy.

4.
Circ J ; 67(6): 505-10, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12808267

ABSTRACT

The present study investigates whether lower-limb dominant exercise training in patients with chronic heart failure (CHF) improves endothelial function primarily in the trained lower extremities or equally in the upper and lower extremities. Twenty-eight patients with CHF were randomized to the exercise or control group. The exercise group underwent cycle ergometer training for 3 months while controls continued an inactive sedentary lifestyle. Exercise capacity (6-min walk test) and flow-mediated vasodilation in the brachial and posterior tibial arteries were evaluated. After 3 months, walking performance increased only in the exercise group (488+/-16 to 501+/-14 m [control]; 497+/-23 to 567+/-39 m [exercise, p<0.05]). The flow-mediated vasodilation in the brachial arteries did not change in either group (4.2+/-0.5 to 4.5+/-0.4% [control]; 4.3+/-0.5 to 4.6+/-0.4% [exercise]), but that in the posterior tibial arteries increased only in the exercise group (4.1+/-0.5 to 4.1+/-0.3% [control]; 3.6+/-0.3 to 6.4+/-0.6% [exercise, p<0.01]). Cycle ergometer training improved flow-mediated vasodilation in the trained lower limbs, but not in the untrained upper limbs. Exercise training appears to correct endothelial dysfunction predominantly by a local effect in the trained extremities.


Subject(s)
Arm/blood supply , Endothelium, Vascular/physiopathology , Exercise Therapy , Heart Failure/therapy , Leg/blood supply , Brachial Artery/diagnostic imaging , Brachial Artery/physiopathology , Endothelin-1/blood , Exercise Tolerance , Female , Heart Failure/blood , Heart Failure/physiopathology , Humans , Hyperemia/physiopathology , Male , Middle Aged , Organ Specificity , Tibial Arteries/diagnostic imaging , Tibial Arteries/physiopathology , Ultrasonography , Vasodilation
5.
J Cardiol ; 40(1): 19-24, 2002 Jul.
Article in Japanese | MEDLINE | ID: mdl-12166245

ABSTRACT

A 49-year-old woman was admitted to our hospital because of frequent postprandial esophageal angina. After successful pyloric plasty, chest oppression lasting 5 to 15 min developed postprandially as well as symptoms of dumping syndrome. Electrocardiography showed ST-segment elevation in the II, III, aVf and precordial leads (V2 to V6). Finally, giant positive T waves and U waves were uniquely noted in the V1 to V5 leads. Intracoronary administration of acetylcholine (20 micrograms) provoked severe diffuse spasm in both right and left coronary arteries, chest pain and ST elevation. The conventional treatment for vasospastic angina, such as Ca2+ antagonists, nitrates and K channel opener, achieved no response. However, the combination with serotonergic receptor blockade reduced anginal attack. These findings suggest that the spastic angina in this case was partly caused by serotonin.


Subject(s)
Angina Pectoris/drug therapy , Coronary Vasospasm/drug therapy , Dumping Syndrome/drug therapy , Esophagectomy/adverse effects , Serotonin Antagonists/therapeutic use , Dumping Syndrome/etiology , Eating , Esophageal Neoplasms/surgery , Female , Humans , Middle Aged , Serotonin/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...